You have accessJournal of UrologyKidney Cancer: Advanced I1 Apr 2015PD35-01 HOW LONG SHOULD BE EXTENDED FOLLOW UP AFTER SURGERY FOR RENAL CANCER? RETROSPECTIVE ANALYSIS OF A COHORT OF PATIENTS WITH MORE THAN 10 YEARS OF FOLLOW UP Francesca Carobbio, Alessandro Antonelli, Mario Sodano, Maria Furlan, Giacomo Galvagni, Alberto Cozzoli, Tiziano Zanotelli, and Claudio Simeone Francesca CarobbioFrancesca Carobbio More articles by this author , Alessandro AntonelliAlessandro Antonelli More articles by this author , Mario SodanoMario Sodano More articles by this author , Maria FurlanMaria Furlan More articles by this author , Giacomo GalvagniGiacomo Galvagni More articles by this author , Alberto CozzoliAlberto Cozzoli More articles by this author , Tiziano ZanotelliTiziano Zanotelli More articles by this author , and Claudio SimeoneClaudio Simeone More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.2224AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES There is no agreement in literature on the duration of follow up after surgery for renal cell carcinoma (RCC). The present study analyzes the oncological outcome in a large cohort of patients followed at least for 10 years. METHODS Retrospective consultation of a database that stores the data of more than 2300 consecutive patients submitted to surgery for RCC at a tertiary academic institution, from 1983 to 2013. All the patients underwent to a tailored follow up protocol extended for an indefinite period of time For the present study were retrieved the records of patients with M0 RCC followed for a minimum of 10 years, during which no progression of the disease was detected. The rate and features of progression and survival were analyzed. RESULTS Were included into the study 554 patients (231 female, 323 male, medium age 59.3+/-11.6 ys) with a M0 RCC, followed for a median follow up time of 15.1 years (range 11.2-18.1 yrs), submitted to partial (131 cases) or radical nephrectomy (423 cases); the mean tumor diameter was 5.1 cm (range 3.0-6.5 cm); the pathological stage was 1 in 386 cases (70.3%), 2 in 53 (9.7%), 3 in 104 (18.9%) e 4 in 6 (1.1%); the grading was 1 in 85 (16.1%), 2 in 301 (56.9%), 3 in 113 (21.4%) e 4 in 30 (5.7%); histology was consistent with clear cell RCC cell in 477 cases (86.1%), papillary in 40 (7.2%), chromofobe in 27 (4.9%), other in 9 (1.6%). The cancer-specific survival was 98.2% and 96.0% at 15 and 20 years, respectively. A progression was observed in 29 patients (5.2%) after a median time of 161 months (range 132-172 months) from surgery. The sites of progression were: the contralateral kidney in 10 cases (1.8%), lung in 5 (0.9%), bone in 1 (0.2%), liver in 1 (0.2%), some other atypical sites in 5 (0.9%), multiple sites in 4 (0.7%), a local relapse in 3 cases (0.6%). Through a logistic regression analysis, was found that the pathological stage was the only independent factor related to progression. CONCLUSIONS The risk of progression after surgery for RCC after ten years of negative follow up, is around 5%, related to pathological stage, and the most frequent sites involved are the contralateral kidney and the lung. Controls can be suspended after 10 years of follow up in patients with pT1 RCC. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e759 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Francesca Carobbio More articles by this author Alessandro Antonelli More articles by this author Mario Sodano More articles by this author Maria Furlan More articles by this author Giacomo Galvagni More articles by this author Alberto Cozzoli More articles by this author Tiziano Zanotelli More articles by this author Claudio Simeone More articles by this author Expand All Advertisement Advertisement PDF DownloadLoading ...
Read full abstract